Targeting multiple biological pathways as a strategy to improve the treatment of cancer

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3309-3310

  O'Reilly, Michael S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CANCER THERAPY; EDITORIAL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NOTE;

EPIDERMAL GROWTH FACTOR RECEPTOR;

HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036846926     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Folkman, J. Clinical applications of angiogenesis research. N. Engl. J. Med., 333: 1757-1763, 1995.
2. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
3. O'Reilly, M. S., and Fidler, I. J. The development of antiangiogenic agents for the clinic. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Progress in Oncology 2002, pp. 129-157. Sudbury: Jones and Bartlett Publishers, Inc., 2002.
4. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
5. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature (Lond.), 390: 404-407, 1997.
6. Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A., Ebb, D., Smith, P. S., and Folkman, J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α-2a. Pediatrics, 103: 1145-1149, 1999.
7. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (Wash. DC), 279: 377-380, 1998.
8. St. Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. Genes expressed in human tumor endothelium. Science (Wash. DC), 289: 1197-202, 2000.
9. Baker, C. H., Solorzano, C. C., and Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 62: 1996-2003, 2002.
10. Hirata, A., Ogawa, S-I., Kometani, T., Kuwano, T., Naito, S., Kuwano, M., and Ono, M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res., 62: 2554-2560, 2002.
11. Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., Feyereislova, A., Swaisland, H., and Rowinsky, E. K. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J. Clin. Oncol., 20: 2240-2250, 2002.
12. Kuenen, B. C., Rosen, L., Smit, E. F., Parson, M. R. N., Levi, M., Ruijter, R., Huisman, H., Kedde, M. A., Noordhuis, P., van der Vijgh, W. J. F., Peters, G. J., Cropp, G. F., Scigalla, P., Hoekman, K., Pinedo, H. M., and Giaccone, G. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol., 20: 1657-1667, 2002.
13. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science (Wash. DC), 295: 1526-1528, 2002.
14. Viloria-Petit, A., Crombet, T., Jothy, S., Hicklin, D., Bohlen, P., Schlaeppi, J. M., Rak, J., and Kerbel, R. S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res., 61: 5090-101, 2001.
15. Relf, M., LeJeune, S., Scott, P. A., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, R., Bicknell, R., and Harris, A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57: 963-969, 1997.
16. O'Reilly, M. S. The combination of antiangiogenic therapy with other modalities. Cancer J. 8(Suppl. 1): S89-S99, 2002.
17. Li, M., Ye, C., Feng, C., Riedel, F., Liu, X., Zeng, Q., and Grandis, J. R. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin. Cancer Res., 8: 3570-3578, 2002.